Repare Therapeutics Presents Initial Clinical P-I/II Trial (TRESR) and (ATTACC) Results of Camonsertib + Three PARP Inhibitors for Solid Tumors at AACR 2023
Shots:
- The P-I/II study (TRESR) evaluating camonsertib + talazoparib or gemcitabine in 451 patients. Additionally, initial data from the P-Ib/II study (ATTACC) of camonsertib + niraparib or olaparib in 108 patients
- The results showed durable clinical benefit across tumor types & different genomic alterations regardless of choice of PARPi & presence of Pt resistance, CBR (48%). In patients with Pt-resistant & non-Pt-resistant tumors, ORR (12% & 13%) & CBR (49% & 46%)
- Benefit in late-line ovarian cancer reported i.e., 32% overall response, 58% CBR & mPFS of ~7mos. with >16wks. treatment, early ctDNA molecular responses in 66% confirm the antitumor activity of low dose intermittent PARPi + ATRi therapy, MRR was higher in clinical benefits patients (83%) over those without (48%); in patients with prior PARPi exposure (57%) & Pt resistance (64%)
Ref: Business wire | Image: Repare Therapeutics
Related News:- BMS Signs an Exclusive Worldwide Agreement with Repare Therapeutics to Identify Multiple Precision Oncology Therapies
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
